4d Pharma PLC
19 April 2021
4D pharma collaborates with Parkinson's UK to establish Patient
Leeds, UK, April 19, 2021 - 4D pharma plc (AIM: DDDD; NASDAQ:
LBPS), a pharmaceutical company leading the development of Live
Biotherapeutic products (LBPs) - a novel class of drug derived from
the microbiome, today announces a collaboration with Parkinson's
UK, a non-profit organization focused on advancing the
understanding of Parkinson's disease and improving treatments, to
establish a Patient Advisory Board.
The Patient Advisory Board (PAB) will be comprised of people
living with Parkinson's. Supported by Parkinson's UK, the PAB will
provide valuable patient-centric perspective to 4D pharma as it
continues to advance novel Live Biotherapeutics into the clinic to
treat neurodegenerative conditions such as Parkinson's. The PAB
will also focus on raising awareness of the issues people with
Parkinson's face with current treatment options.
"4D pharma selected to work with Parkinson's UK to represent the
patient community as the largest charitable funder of Parkinson's
research in Europe. The contributions of our Patient Advisory
Board, with the support of Parkinson's UK, will be vital to 4D
pharma's efforts to not only develop novel therapeutics for this
devastating condition, but also promote a dialogue and partnership
with the Parkinson's patient community," said Alex Stevenson, Chief
Scientific Officer, 4D pharma. "Parkinson's is the fastest growing
neurological condition in the world. It is important that
therapeutics in development address the issues of patients. By
working with Parkinson's UK and our Patient Advisory Board, 4D
pharma is better able to engage Parkinson's patients with our
clinical programs as we work to bring the first Live Biotherapeutic
for the treatment of this condition into the clinic."
"145,000 people are currently living with Parkinson's in the UK
alone. There is a desperate need for new and better treatments. To
develop these, it is vital to involve people affected by
Parkinson's at every stage of research - from setting priorities
and making decisions about funding to designing trials," said
Natasha Ratcliffe, Research Involvement Manager at Parkinson's UK.
"We're delighted to be working with innovative companies like 4D
pharma that share these values with us and are bringing new
approaches to developing transformational new treatments for
Parkinson's. The Patient Advisory Board will enable people affected
by Parkinson's to have input into the development of this novel
Today's announcement builds on 4D pharma's previously announced
partnership with the Michael J. Fox Foundation-sponsored
Parkinson's Progression Markers Initiative (PPMI), where 4D pharma
will collaborate as an industry partner. Through this partnership
4D pharma representatives join the PPMI Partner Scientific Advisory
Board closely involved in the design and execution of the landmark
PPMI study, as well as additional PPMI Working Groups to discuss
PPMI data and address Parkinson's clinical trial challenges.
4D pharma continues to progress plans for a first-in-human
clinical trial in Parkinson's disease patients of its oral single
strain Live Biotherapeutics.
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform,
MicroRx(R), that rationally identifies Live Biotherapeutics based
on a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has six clinical programmes,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumours, a Phase I
study of MRx0518 in patients with pancreatic cancer, a Phase I/II
study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in
patients hospitalised with COVID-19, and Blautix(R) in Irritable
Bowel Syndrome (IBS) which has completed a successful Phase II
trial. Preclinical-stage programmes include candidates for CNS
disease such as Parkinson's disease and other neurodegenerative
conditions. The Company has a research collaboration with MSD, a
tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to
discover and develop Live Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
About Parkinson's and Parkinson's UK
Parkinson's is what happens when the brain cells that make
dopamine start to die. There are more than 40 symptoms, from tremor
and pain to anxiety. Some are treatable, but the drugs can have
serious side effects. It gets worse over time and there's no cure.
Parkinson's is the fastest growing neurological condition in the
world. Around 145,000 people in the UK have Parkinson's.
For more facts and statistics, please click here .
Further information, advice and support is available on the
Parkinson's UK website, www.parkinsons.org.uk .
This announcement contains "forward-looking statements." All
statements other than statements of historical fact contained in
this announcement, including without limitation statements
regarding 4D's pharma's plans for an in-human clinical trial in
Parkinson's patients and the contributions of the PAB, are
forward-looking statements within the meaning of Section 27A of the
United States Securities Act of 1933, as amended (the "Securities
Act"), and Section 21E of the United States Securities Exchange Act
of 1934, as amended (the "Exchange Act"). Forward-looking
statements are often identified by the words "believe," "expect,"
"anticipate," "plan," "intend, " "foresee," "should," "would,"
"could," "may," "estimate," "outlook" and similar expressions,
including the negative thereof. The absence of these words,
however, does not mean that the statements are not forward-looking.
These forward-looking statements are based on the Company's current
expectations, beliefs and assumptions concerning future
developments and business conditions and their potential effect on
the Company. While management believes that these forward-looking
statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be
those that it anticipates.
All of the Company's forward-looking statements involve known
and unknown risks and uncertainties, some of which are significant
or beyond its control, and assumptions that could cause actual
results to differ materially from the Company's historical
experience and its present expectations or projections. The
foregoing factors and the other risks and uncertainties that could
cause actual results to differ materially include potential delays
in its clinical studies, the failure of the PAB to provide
meaningful insights into the development of treatments and those
additional risks and uncertainties described the documents filed by
the Company with the US Securities and Exchange Commission ("SEC").
The Company wishes to caution you not to place undue reliance on
any forward-looking statements, which speak only as of the date
hereof. The Company undertakes no obligation to publicly update or
revise any of its forward-looking statements after the date they
are made, whether as a result of new information, future events or
otherwise, except to the extent required by law.
Investor Relations: firstname.lastname@example.org
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496
Philip Davies / Iqra Amin / James Fischer (Corporate
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
Dominic Wilson / Phil Walker
Stern Investor Relations, Inc. +1-212-362-1200
Julie Seidel Julie.email@example.com
Image Box Communications +44 (0)20 8943 4685
Neil Hunter / Michelle Boxall
firstname.lastname@example.org / email@example.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact firstname.lastname@example.org or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
April 19, 2021 02:00 ET (06:00 GMT)